A Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia

PHASE2CompletedINTERVENTIONAL
Enrollment

432

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

April 30, 2014

Study Completion Date

July 31, 2014

Conditions
Schizophrenia
Interventions
DRUG

ABT-126

ABT-126 Middle Dose

DRUG

ABT-126

ABT-126 Low Dose

DRUG

ABT-126

ABT-126 High Dose

DRUG

Placebo

Placebo

Trial Locations (61)

10312

Site Reference ID/Investigator# 75053, Staten Island

11516

Site Reference ID/Investigator# 72694, Cedarhurst

14623

Site Reference ID/Investigator# 75137, Rochester

19139

Site Reference ID/Investigator# 75413, Philadelphia

30060

Site Reference ID/Investigator# 74893, Marietta

30308

Site Reference ID/Investigator# 75653, Atlanta

60169

Site Reference ID/Investigator# 76533, Hoffman Estates

60640

Site Reference ID/Investigator# 72697, Chicago

67214

Site Reference ID/Investigator# 75056, Wichita

75115

Site Reference ID/Investigator# 72696, DeSoto

75231

Site Reference ID/Investigator# 74553, Dallas

77008

Site Reference ID/Investigator# 75055, Houston

77098

Site Reference ID/Investigator# 74896, Houston

90502

Site Reference ID/Investigator# 72695, Torrance

90631

Site Reference ID/Investigator# 75057, La Habra

90650

Site Reference ID/Investigator# 77655, Norwalk

90660

Site Reference ID/Investigator# 74453, Pico Rivera

90706

Site Reference ID/Investigator# 74894, Bellflower

91710

Site Reference ID/Investigator# 74434, Chino

91776

Site Reference ID/Investigator# 73974, San Gabriel

91950

Site Reference ID/Investigator# 72693, National City

92025

Site Reference ID/Investigator# 73213, Escondido

92056

Site Reference ID/Investigator# 73977, Oceanside

92102

Site Reference ID/Investigator# 86973, San Diego

92103

Site Reference ID/Investigator# 75140, San Diego

92408

Site Reference ID/Investigator# 98016, San Bernardino

92506

Site Reference ID/Investigator# 74898, Riverside

92626

Site Reference ID/Investigator# 76593, Costa Mesa

92705

Site Reference ID/Investigator# 74433, Santa Ana

92804

Site Reference ID/Investigator# 75139, Anaheim

92845

Site Reference ID/Investigator# 72698, Garden Grove

92868

Site Reference ID/Investigator# 73214, Orange

94612

Site Reference ID/Investigator# 74895, Oakland

107076

Site Reference ID/Investigator# 81934, Moscow

109559

Site Reference ID/Investigator# 81935, Moscow

115419

Site Reference ID/Investigator# 79516, Moscow

150003

Site Reference ID/Investigator# 83117, Yaroslavl

190020

Site Reference ID/Investigator# 80673, Saint Petersburg

190121

Site Reference ID/Investigator# 85093, Saint Petersburg

191119

Site Reference ID/Investigator# 97135, Saint Petersburg

Site Reference ID/Investigator# 97137, Saint Petersburg

192019

Site Reference ID/Investigator# 83115, Saint Petersburg

195176

Site Reference ID/Investigator# 97136, Saint Petersburg

197341

Site Reference ID/Investigator# 84733, Saint Petersburg

357034

Site Reference ID/Investigator# 79520, Stavropol

399083

Site Reference ID/Investigator# 79517, Lipetsk

410028

Site Reference ID/Investigator# 81933, Saratov

410060

Site Reference ID/Investigator# 79514, Saratov

420061

Site Reference ID/Investigator# 94528, Kazan'

620028

Site Reference ID/Investigator# 97138, Yekaterinburg

620030

Site Reference ID/Investigator# 79515, Yekaterinburg

630064

Site Reference ID/Investigator# 83116, Novosibirsk

672090

Site Reference ID/Investigator# 94476, Chita

06519

Site Reference ID/Investigator# 75136, New Haven

TW8 8DS

Site Reference ID/Investigator# 81938, Brentford

EH10 5HF

Site Reference ID/Investigator# 81940, Edinburgh

SE5 8AF

Site Reference ID/Investigator# 81939, London

W6 8RP

Site Reference ID/Investigator# 92813, London

NE4 5PL

Site Reference ID/Investigator# 81937, Newcastle upon Tyne

OX3 7JX

Site Reference ID/Investigator# 81943, Oxford

PR5 6YA

Site Reference ID/Investigator# 82238, Preston

All Listed Sponsors
lead

AbbVie (prior sponsor, Abbott)

INDUSTRY

NCT01655680 - A Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia | Biotech Hunter | Biotech Hunter